<DOC>
	<DOC>NCT00729469</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.</brief_summary>
	<brief_title>Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Naturally or surgically menopausal Moderate or severe symptoms of vaginal atrophy 5% or fewer superficial cells in maturation index of vaginal smear Vaginal pH greater than 5.0 Self reported Most Bothersome Symptom of vaginal dryness or vaginal pain associated with sexual activity, with a severity of moderate or severe at randomization Uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine fibroids Current vaginal infection requiring medication Clinically significant abnormal gynecological findings other than signs of vaginal atrophy (e.g. uterine or vaginal prolapse of Grade 2 or higher) Previous participation in any other ospemifene study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Vulvar and vaginal atrophy in postmenopausal women</keyword>
	<keyword>Menopausal symptoms</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Urogenital atrophy</keyword>
</DOC>